Featuring news, events and industry trends

Westchester County Biosciences Accelerator participant, Addinex has been named a Finalist for Fast Company Magazine's 2022 World Changing Ideas Award - Health category. Fast Company is the leading magazine for emerging technology with 875,000 print subscribers and 10.9 million average monthly unique visitors to its website. 

Addinex is focused on preventing opioid misuse, addiction, and overdose, and treating those with Opioid Use Disorder.The Addinex team has also been busy with product and business development having upgraded its medication dispenser and expanded the capabilities of its app to work on multiple platforms, Spanish language, and to monitor addiction treatment medications, including an optional video adherence module. We have been offering demos to gain valuable feedback from potential users.
High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair

Tarrytown headquartered Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) recently hosted the 2022 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global high school competition.

The top winners were honored during two hybrid award ceremonies, the first of which took place on the evening of May 12 and featured Special Award winners. The Grand Awards Ceremony was held on the morning of May 13 and featured the announcement of the top prize of $75,000. In total, awards valued at nearly U.S. $8 million were awarded to the finalists, who were evaluated based on their projects' creativity, innovation and level of scientific inquiry. The competition featured 1,750 young scientists representing 49 states and 63 countries, regions and territories across the world. Among this year’s participants was Tista Goswami, a High School senior from Mamaroneck. Tista -- whose project titled "SMART-Screen: A Point-of-Care COVID-19 Active Replication Detection System"-- recently earned a Grand Prize at the Westchester Science and Engineering Fair.
Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD

Purchase-headquartered Cognition Therapeutics, a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina, presented a poster at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) demonstrating that sigma-2 (σ-2) receptor modulators may restore the homeostatic functioning of retinal pigment epithelial (RPE) cells that is disrupted in dry age-related macular degeneration (dry AMD).

Dry AMD is characterized by a progressive deterioration of the macula, a region of the retina comprised of photoreceptors and RPE cells, which support photoreceptors and are essential for the health of the retina.

Cognition plans to initiate a Phase 2 clinical study with CT1812, its lead σ-2 receptor modulator, in patients with dry AMD in the second half of 2022.
Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Purchase-headquartered Cognition Therapeutics, Inc. a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), announced that Lisa Ricciardi, the Company’s president and CEO and Mary Hamby, Ph.D., vice president of research, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.

A live and archived webcast will be available on the H.C. Wainwright meeting platform and on the Investors section of the company’s website at https://ir.cogrx.com
Sapience Receives Orphan Designation for ST101 to Treat Advanced Melanoma

Harrison headquartered, Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, ST101, for the treatment of advanced melanoma for patients in stages IIB through IV. This is the third orphan drug designation received for the ST101 program, following orphan designations by the FDA for the treatment of AML in April 2018 and for glioma in June 2020.

Orphan Drug Designation is granted to drugs or biological products for the treatment of rare diseases or conditions that impact fewer than 200,000 people in the United States. Incentives that come with the designation include eligibility for federal grants, research and development tax credits, waiver of filing fees, and the potential for a 7-year marketing exclusivity period. The designation does not alter the standard regulatory requirements and process for obtaining marketing approval. ST101 also previously received Fast Track Designation for recurrent GBM and advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy.
Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

Headquartered in Ardsley, Acorda Therapeutics, Inc. and Biopas Laboratories announced that they have entered into distribution and supply agreements to commercialize INBRIJA® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.

Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of the selling price of INBRIJA in Latin America in exchange for supply of the product. Acorda will also receive sales-based milestones. Biopas will have the exclusive distribution rights to INBRIJA in nine countries within Latin America, including Brazil and Mexico. According to current population estimates, there are at least 400,000 people living with Parkinson's disease in Latin America1. Biopas plans on seeking marketing authorization in all countries to make Inbrija available for patients as quickly as possible.
Westchester County Biosciences Accelerator Participates in Pitch Day 2022

Members of the third cohort of the Westchester County Biosciences Accelerator (WCBA) participated in the annual Pitch Day event which took place May 12 – 13.
Twelve ventures pitched this year at the hybrid event, which took place at the FIAF French Institute Alliance Française: Florence Gould Hall, as well as virtually. The event featured opening remarks from WCBA Program Director Mary Howard, followed by a panel of distinguished WCBA alumni, as well as alumni from other regional programs including the Accelerator for Biosciences in Connecticut (ABCT), and Entrepreneurship Lab NYC (ELabNYC).
Burke Neurological Institute Hosts Hope for Stroke:
2022 McDowell Symposium & Awards

Date: May 20
Time: 8:30 a.m. - 4:00 p.m.
Business Incubator Association of New York State, Inc.
Opportunities to Work with NIH on Your Product Pipeline

Date: May 25
Time: 10:00 a.m. - 11:00 a.m.

Have good news to share from
Westchester’s biosciences ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.